Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.29 | 7e-18 |
mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.29 | 2e-14 |
mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.22 | 5e-11 |
mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.24 | 6e-11 |
mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.34 | 5e-08 |
mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.35 | 6e-08 |
mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-07 |
mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.17 | 4e-06 |
mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.17 | 1e-05 |
mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.23 | 1e-05 |